NCT03284827View on ClinicalTrials.gov

Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement

PHASE4CompletedINTERVENTIONAL
Enrollment

235

Participants

Timeline

Start Date

March 15, 2018

Primary Completion Date

October 26, 2021

Study Completion Date

November 5, 2021

Conditions
Aortic Valve Stenosis
Interventions
DRUG

NOAC

edoxaban (60 mg once daily \[OD\]) for at least 6 months

DRUG

DAPT

clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD) for at least 6 months

Trial Locations (5)

Unknown

Queen Mary Hospital, Hong Kong

Bundang CHA Hospital, Seongnam

Cheng Hsin General Hospital, Taipei

National Taiwan University Hospital, Taipei

138-736

Asan Medical Center, Seoul

All Listed Sponsors
collaborator

CardioVascular Research Foundation, Korea

OTHER

collaborator

Daiichi Sankyo Korea Co., Ltd.

INDUSTRY

lead

Duk-Woo Park, MD

OTHER

NCT03284827 - Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement | Biotech Hunter | Biotech Hunter